HER2阻害剤の世界市場レポート 2025年

HER2阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2029年には136億1,000万米ドルに成長し、CAGRは9.0%となります。予測期間の成長は、患者中心のケアモデル、規制の変更と承認、薬剤耐性管理、世界市場への浸透、適応症の拡大、精密腫瘍学の採用などに起因すると考えられます。予測期間の主な動向には、患者擁護と意識向上、臨床試験と調査、早期発見と診断、精密医療とバイオマーカー検査、アジュバント療法とネオアジュバント療法などがあります。

世界の乳がん罹患率の増加は、予測期間におけるHER-2阻害剤市場の成長に大きく寄与する要因になると予想されます。2022年1月現在、米国がん協会は米国だけで190万人が新たにがんと診断され、60万9,360人ががん関連で死亡するという予測を報告しています。乳がんは、肺がん、前立腺がん、腸がんと並んで、世界的に最も多い4種類のがんにランクされ、合わせて新規がん患者全体の43％を占めています。このような乳がん罹患率の上昇から、今後数年間はHER-2阻害剤の需要増加が予想されます。

乳がんの治療とケアを強化することを目的とした政府のイニシアチブは、今後のHER2阻害剤市場の成長を促進すると予想されます。このような取り組みには、乳がんと診断された患者のケアへのアクセス性、手頃な価格、質を向上させることを目的とした政策、資金提供、プログラムが含まれます。このような政府の取り組みにより、乳がん治療薬であるHER2阻害剤へのアクセスが助成プログラムや研究資金を通じて増加し、患者の治療と転帰が改善されています。例えば、スイスに本部を置く政府間機関である世界保健機関（WHO）は2023年2月、新たな「世界乳がんイニシアチブフレームワーク」を発表し、2040年までに乳がんから250万人の命を救うという目標を達成するためのロードマップを提示しました。その結果、乳がんの治療とケアを強化する政府の取り組みが、HER2阻害剤市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界HER2阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のHER2阻害剤市場：成長率分析
• 世界のHER2阻害剤市場の実績：規模と成長, 2019-2024
• 世界のHER2阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界HER2阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のHER2阻害剤市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単剤療法
• 併用療法
• 世界のHER2阻害剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 扁平上皮がん
• 腺がん
• 大細胞がん
• 乳がん
• その他の用途
• 世界のHER2阻害剤市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他のエンドユーザー
• 世界のHER2阻害剤市場単剤療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• シングルエージェント HER2阻害剤
• HER2標的療法
• 世界のHER2阻害剤市場、併用療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• HER2阻害剤化学療法との併用
• HER2阻害剤標的療法との併用
• HER2阻害剤ホルモン療法との併用

第7章 地域別・国別分析

• 世界のHER2阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のHER2阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• HER2阻害剤市場：競合情勢
• HER2阻害剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly International Corp.
• C.H. Boehringer Sohn AG & Co. KG
• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Company Limited
• Catalent Inc.
• Ipsen SA
• the Pierre Fabre Group
• Biocon Biopharmaceuticals Pvt. Ltd.
• Innovent Biologics Inc.
• Halozyme Therapeutics Inc.
• Seattle Genetics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• HER2阻害剤市場2029：新たな機会を提供する国
• HER2阻害剤市場2029：新たな機会を提供するセグメント
• HER2阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

HER2 inhibitors constitute a group of medications employed in treating HER2-low and HER2-positive breast cancers across various stages, from early to metastatic. These drugs target the HER2 receptor proteins present on breast cancer cells, hindering the reception of growth signals in HER2-positive breast cancer.

Treatments mainly consist of monotherapy and combination therapy. Monotherapy involves using a single medication for treating specific conditions or diseases. These treatments find applications in various cancer types such as squamous cell carcinoma, adenocarcinoma, large cell carcinoma, as well as breast cancer, and are utilized across healthcare sectors including hospitals, clinics, and other medical settings.

The HER2 inhibitors market research report is one of a series of new reports from The Business Research Company that provides HER2 inhibitors market statistics, including HER2 inhibitors industry global market size, regional shares, competitors with a HER2 inhibitors market share, detailed HER2 inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the HER2 inhibitors industry. This HER2 inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The HER2 inhibitors market size has grown strongly in recent years. It will grow from $8.77 billion in 2024 to $9.64 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to biotechnological advances, clinical trial success, shift in treatment paradigm, research and development investments, patient outcomes improvement.

The HER2 inhibitors market size is expected to see strong growth in the next few years. It will grow to $13.61 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to patient-centric care models, regulatory changes and approvals, drug resistance management, global market penetration, expanded indications, precision oncology adoption. Major trends in the forecast period include patient advocacy and awareness, clinical trials and research, early detection and diagnosis, precision medicine and biomarker testing, adjuvant and neoadjuvant therapy.

The increasing incidence of breast cancer cases worldwide is expected to be a significant factor contributing to the growth of the HER-2 inhibitors market in the forecast period. As of January 2022, the American Cancer Society reported projections of 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the United States alone. Breast cancer ranks among the four most common types of cancer globally, alongside lung, prostate, and bowel cancer, collectively accounting for 43% of all new cancer cases. Given this rise in breast cancer incidence, there is an anticipated increase in the demand for HER-2 inhibitors in the coming years.

Government initiatives aimed at enhancing breast cancer care and treatment are expected to drive the growth of the HER2 inhibitors market in the future. These initiatives include policies, funding, and programs designed to improve the accessibility, affordability, and quality of care for individuals diagnosed with breast cancer. Such government efforts have increased access to HER2 inhibitors, a treatment for breast cancer, through subsidized programs and research funding, thereby improving care and outcomes for patients. For example, in February 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, unveiled a new Global Breast Cancer Initiative Framework, providing a roadmap to achieve the goal of saving 2.5 million lives from breast cancer by 2040. Consequently, government initiatives to enhance breast cancer care and treatment are fueling the growth of the HER2 inhibitors market.

Prominent companies in the HER2 inhibitor market are strategically concentrating on the development of treatments for specific breast cancer subtypes to gain a competitive advantage. One such focus is on addressing HER2-low breast cancer, a newly defined subset of HER2-negative breast cancer characterized by tumors that do not overexpress or produce an excess of the HER2 protein. In August 2022, AstraZeneca PLC, a leading UK-based pharmaceutical and biotechnology company, achieved a milestone as the U.S. Food and Drug Administration (FDA) granted approval for Enhertu (fam-trastuzumab deruxtecan-nxki). Enhertu is recognized as the first HER2-directed therapy designed for patients with HER2-low metastatic breast cancer. Administered through intravenous infusion, Enhertu is prescribed for adults who have undergone prior metastatic chemotherapy or experienced disease recurrence within six months of completing adjuvant chemotherapy, targeting HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.

Major players in the HER2 inhibitor market are directing their efforts towards developing treatments for pre-treated HR+/HER2-metastatic breast cancer. This particular breast cancer subtype, characterized by the presence of hormone receptors (HR+), is the focus of therapeutic development. In February 2023, Gilead Sciences, Inc., a prominent US-based biopharmaceutical company, received approval from the U.S. FDA for Trodelvy (sacituzumab govitecan-hziy). Trodelvy is intended for the treatment of adults with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer. This approval is specifically granted for patients who have undergone prior endocrine-based therapies and two additional systemic treatments in the metastatic setting, addressing the needs of this particular patient population. These strategic initiatives underline the companies' commitment to developing targeted therapies for specific breast cancer subtypes, contributing to their competitive positioning in the HER2 inhibitor market.

In December 2023, Pfizer, a US-based multinational pharmaceutical and biotechnology company, acquired Seagen for around $43 billion. This acquisition is intended to strengthen Pfizer's leadership in oncology by incorporating Seagen's advanced cancer treatments and technologies. This strategic move aims to expedite the development of transformative therapies for cancer patients. Seagen is a US-based biotechnology firm that specializes in providing HER2 inhibitors.

Major companies operating in the HER2 inhibitors market include Pfizer Inc., Johnson & Johnson Services Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly International Corp., C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Catalent Inc., Ipsen SA, the Pierre Fabre Group, Biocon Biopharmaceuticals Pvt. Ltd., Innovent Biologics Inc., Halozyme Therapeutics Inc., Seattle Genetics Inc., Zymeworks Inc., Puma Biotechnology Inc., MacroGenics Inc., Mersana Therapeutics Inc., Cellestia Biotech AG

North America was the largest region in the HER2 inhibitors market in 2024. Middle East is expected to be the fastest-growing region in the HER2 inhibitors market report during the forecast period. The regions covered in the her2 inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the her2 inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The HER2 inhibitor market consists of sales of lapatinib, neratinib, tucatinib, and pyrotinib. Values in this market are ""factory gate values,"" that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

HER2 Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on her2 inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for her2 inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The her2 inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Monotherapy; Combination Therapy
• 2) By Application: Squamous Cell Carcinoma; Adenocarcinoma; Large Cell Carcinoma; Breast Cancer; Other Applications
• 3) By End User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Monotherapy: Single-Agent HER2 Inhibitors; Targeted HER2 Therapies
• 2) By Combination Therapy: HER2 Inhibitors Combined With Chemotherapy; HER2 Inhibitors Combined With Targeted Therapies; HER2 Inhibitors Combined With Hormonal Therapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. HER2 Inhibitors Market Characteristics

3. HER2 Inhibitors Market Trends And Strategies

4. HER2 Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global HER2 Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global HER2 Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global HER2 Inhibitors Market Growth Rate Analysis
• 5.4. Global HER2 Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global HER2 Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global HER2 Inhibitors Total Addressable Market (TAM)

6. HER2 Inhibitors Market Segmentation

• 6.1. Global HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy
• 6.2. Global HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Squamous Cell Carcinoma
• Adenocarcinoma
• Large Cell Carcinoma
• Breast Cancer
• Other Applications
• 6.3. Global HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End Users
• 6.4. Global HER2 Inhibitors Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Agent HER2 Inhibitors
• Targeted HER2 Therapies
• 6.5. Global HER2 Inhibitors Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HER2 Inhibitors Combined With Chemotherapy
• HER2 Inhibitors Combined With Targeted Therapies
• HER2 Inhibitors Combined With Hormonal Therapies

7. HER2 Inhibitors Market Regional And Country Analysis

• 7.1. Global HER2 Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global HER2 Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific HER2 Inhibitors Market

• 8.1. Asia-Pacific HER2 Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China HER2 Inhibitors Market

• 9.1. China HER2 Inhibitors Market Overview
• 9.2. China HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India HER2 Inhibitors Market

• 10.1. India HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan HER2 Inhibitors Market

• 11.1. Japan HER2 Inhibitors Market Overview
• 11.2. Japan HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia HER2 Inhibitors Market

• 12.1. Australia HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia HER2 Inhibitors Market

• 13.1. Indonesia HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea HER2 Inhibitors Market

• 14.1. South Korea HER2 Inhibitors Market Overview
• 14.2. South Korea HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe HER2 Inhibitors Market

• 15.1. Western Europe HER2 Inhibitors Market Overview
• 15.2. Western Europe HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK HER2 Inhibitors Market

• 16.1. UK HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany HER2 Inhibitors Market

• 17.1. Germany HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France HER2 Inhibitors Market

• 18.1. France HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy HER2 Inhibitors Market

• 19.1. Italy HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain HER2 Inhibitors Market

• 20.1. Spain HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe HER2 Inhibitors Market

• 21.1. Eastern Europe HER2 Inhibitors Market Overview
• 21.2. Eastern Europe HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia HER2 Inhibitors Market

• 22.1. Russia HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America HER2 Inhibitors Market

• 23.1. North America HER2 Inhibitors Market Overview
• 23.2. North America HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA HER2 Inhibitors Market

• 24.1. USA HER2 Inhibitors Market Overview
• 24.2. USA HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada HER2 Inhibitors Market

• 25.1. Canada HER2 Inhibitors Market Overview
• 25.2. Canada HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America HER2 Inhibitors Market

• 26.1. South America HER2 Inhibitors Market Overview
• 26.2. South America HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil HER2 Inhibitors Market

• 27.1. Brazil HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East HER2 Inhibitors Market

• 28.1. Middle East HER2 Inhibitors Market Overview
• 28.2. Middle East HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa HER2 Inhibitors Market

• 29.1. Africa HER2 Inhibitors Market Overview
• 29.2. Africa HER2 Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa HER2 Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa HER2 Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. HER2 Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. HER2 Inhibitors Market Competitive Landscape
• 30.2. HER2 Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. HER2 Inhibitors Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Eli Lilly International Corp.
• 31.6. C.H. Boehringer Sohn AG & Co. KG
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Daiichi Sankyo Company Limited
• 31.9. Catalent Inc.
• 31.10. Ipsen SA
• 31.11. the Pierre Fabre Group
• 31.12. Biocon Biopharmaceuticals Pvt. Ltd.
• 31.13. Innovent Biologics Inc.
• 31.14. Halozyme Therapeutics Inc.
• 31.15. Seattle Genetics Inc.

32. Global HER2 Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The HER2 Inhibitors Market

34. Recent Developments In The HER2 Inhibitors Market

35. HER2 Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 HER2 Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 HER2 Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 HER2 Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer